CJC-1295 DAC 5mg

Mechanisms of Pituitary Growth Hormone Stimulation

Scientists utilize CJC-1295 DAC to investigate the stimulation of the anterior pituitary gland and the subsequent release of growth hormone (GH). As a synthetic analogue of the naturally occurring Growth Hormone Releasing Hormone (GHRH), this peptide binds to specific receptors to trigger a biological signaling cascade. Specifically, its primary function involves replicating the pulsatile nature of endogenous GHRH to enhance systemic hormone circulation. Consequently, researchers can explore the resulting elevations in plasma GH levels within various preclinical laboratory models.

Drug Affinity Complex and Extended Bioavailability

The defining characteristic of this compound is the integrated Drug Affinity Complex (DAC) technology, which significantly alters its pharmacokinetic profile. Specifically, this innovation allows the peptide to form stable covalent bonds with serum albumin once introduced into the blood plasma. Therefore, the bio-conjugation process prevents rapid enzymatic degradation and extends the half-life to approximately 6–8 days. Thus, researchers often select this version over non-DAC alternatives when longitudinal studies require a steady, sustained release of growth hormone rather than acute peaks.

Synergistic Modulation of the Liver and IGF-1

Moreover, the administration of CJC-1295 DAC plays a vital role in the indirect modulation of Insulin-like Growth Factor-1 (IGF-1). Once the pituitary gland releases growth hormone, it travels to the liver to stimulate the synthesis of IGF-1. Notably, these two hormones work in tandem to regulate cellular proliferation and musculoskeletal tissue repair. Consequently, the peptide serves as an essential tool for researching age-related hormonal decline and the metabolic pathways associated with tissue regeneration and bone density.

Structural Precision and Chemical Specifications

Similarly, the molecular architecture of CJC-1295 DAC is engineered for high-affinity receptor binding and chemical stability. Specifically, the sequence includes a D-Alanine substitution which further protects the peptide from dipeptidyl peptidase-IV (DPP-IV) cleavage. Therefore, every vial provided by EliteBiogenix undergoes rigorous HPLC verification to ensure the structural integrity and purity of the compound. In addition, the lyophilized format ensures that the peptide remains stable during transit and long-term laboratory storage.

EliteBiogenix Quality and Handling Protocols

Finally, our laboratory ensures that every batch of CJC-1295 DAC reaches a purity level of $\ge$ 98% through advanced mass spectrometry analysis. Notably, this high-purity standard is critical for achieving reproducible data in sensitive endocrine research protocols.

• Sequence: Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-Lys

• Half-Life: 6–8 days via albumin binding technology.

• Storage: Maintain lyophilized vials at -20°C; refrigerate reconstituted samples at 2–8°C.

• Purity: Minimum 98% HPLC verified for consistent research outcomes.

• Compliance: Strictly for in vitro and animal model research; not for human or veterinary use.